Guillevin Loïc, Pagnoux Christian
Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université Paris, Paris, France.
Isr Med Assoc J. 2008 Jan;10(1):89-91.
Treatment of vasculitides has progressed markedly over the past few decades. Recent therapeutic strategies in severe and refractory anti-neutrophil cytoplasmic antibodies-associated vasculitides include immunomodulating methods (e.g., plasma exchanges), products (such as intravenous immunoglobulins) and, more recently, new agents called biotherapies. Some of them (e.g., anti-tumor necrosis factor-alpha and anti-CD20 monoclonal antibodies) have achieved promising results and are now often used to treat severe cases.
在过去几十年中，血管炎的治疗取得了显著进展。针对严重且难治的抗中性粒细胞胞浆抗体相关血管炎的最新治疗策略包括免疫调节方法（如血浆置换）、产品（如静脉注射免疫球蛋白），以及最近出现的称为生物疗法的新型药物。其中一些（如抗肿瘤坏死因子-α和抗CD20单克隆抗体）已取得了令人鼓舞的成果，现在常被用于治疗重症病例。
